Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag146 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Roberta Scafetta und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Bone Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The introduction of CDK4/6 inhibitors (CDK4/6i) has improved outcomes in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC), including in patients with bone metastases. Assessing their comparative effectiveness in real-world settings is crucial.
Methods
This retrospective, multicenter cohort study (January 2019–December 2023; median follow-up 39 months) evaluated the real-world progression-free survival (rwPFS) of abemaciclib, ribociclib, and palbociclib combined with endocrine therapy (ET) in HR+/HER2- mBC patients with bone metastases. Overall survival (OS) was a secondary exploratory endpoint. A total of 1399 patients with ECOG PS 0–1 and at least 12 months of follow-up were included. Analyses used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to adjust for confounding.
Results
Palbociclib showed shorter rwPFS (22 months) compared to abemaciclib (32 months; HR = 1.47, p = 0.001) and ribociclib (35 months; HR = 1.49, p < 0.001). No significant difference was observed between abemaciclib and ribociclib. OS was also lower with palbociclib (47 months) versus abemaciclib (60 months; HR = 1.77, p < 0.001) and ribociclib (64 months; HR = 1.69, p = 0.001). Results were consistent after PSM and IPTW adjustment. CONCLUSION Ribociclib and abemaciclib may provide superior rwPFS and OS compared to palbociclib in HR+/HER2- mBC patients with bone metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico Via Alvaro del Portillo 200, Italy.
- Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128, Roma, Italy.
- Division of Medical Oncology, "G.Martino" University Hospital, Via Consolare Valeria 1, 98124, Messina, Italy.
- Medical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, 01100 Viterbo, Italy.
- Department of Radiological, Oncological and Pathological Science, "Sapienza" University of Rome, Rome, Italy.
- Department of Experimental Medicine, Sapienza University, Rome, Italy.
ORCID-Profile: Sonia Simonetti, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Roberta Caputo, Stefania Gori, Icro Meattini
Zitieren
APA
Scafetta, R., Donato, M., Gullotta, C., Guarino, A., Fiore, C., Sisca, L., Speziale, E., Troiano, R., Foderaro, S., Venuti, F., Vilardi, F. A., Ricozzi, V., Iuliani, M., Simonetti, S., Cavaliere, S., Cortellini, A., La Cesa, A., Botticelli, A., Scagnoli, S., …, & Cretella, E. (2026). Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases. The Oncologist. https://doi.org/10.1093/oncolo/oyag146
Vancouver
Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, et al. Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases. The Oncologist. 2026. doi:10.1093/oncolo/oyag146
BibTeX
@article{Scafetta2026,
author = {Scafetta, Roberta and Donato, Marco and Gullotta, Carla and Guarino, Alessandra and Fiore, Cristina and Sisca, Luisana and Speziale, Elena and Troiano, Raffaella and Foderaro, Simone and Venuti, Fabio and Vilardi, Francesco Antonio and Ricozzi, Valentina and Iuliani, Michele and Simonetti, Sonia and Cavaliere, Silvia and Cortellini, Alessio and La Cesa, Annalisa and Botticelli, Andrea and Scagnoli, Simone and Pisegna, Simona and Criscitiello, Carmen and Chirco, Alessandra and D'Alessandro, Sara and Pedersini, Rebecca and Sposetti, Caterina and Tiberi, Elisa and D'Auria, Giuliana and Vergati, Matteo and Mazzotta, Marco and Caputo, Roberta and Verrazzo, Annarita and Rossino, Maria Grazia and Domati, Federica and Piombino, Claudia and Di Lisa, Francesca Sofia and Filomeno, Lorena and Arcuri, Teresa and Puce, Federica and Riva, Federica and Palleschi, Michela and Sirico, Marianna and Piras, Marta and Stucci, Luigia Stefania and De Lisi, Delia and Orsaria, Paolo and Grasso, Antonella and Ippolito, Edy and Ramella, Sara and Visani, Luca and Bertini, Niccolò and Bonaparte, Ilaria and Gori, Stefania and Rossi, Luigi and Meattini, Icro and Tagliaferri, Barbara and Caffo, Orazio and Bonomo, Maria Vittoria and Portarena, Ilaria and Irelli, Azzurra and Cretella, Elisabetta},
title = {Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag146}
}
EUVIMED